Brandon Twyford

DocwireNews

The final analysis of the BESPOKE CRC study, presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Purvi Shah, MD, of Virginia Cancer Institute, sheds light on the utility of circulating tumor DNA (ctDNA) testing in detecting molecular residual disease (MRD) in patients with stage II and III colorectal cancer (CRC). This prospective, multicenter, observational study underscores the prognostic significance of ctDNA positivity and its potential role in guiding treatment decisions and improving disease-free survival (DFS).
Study Design and Objectives
The BESPOKE CRC study included 1,001 patients with stage II or III CRC who underwent surgical resection. Patients were monitored using a personalized, tumor-informed, 16-plex multiplex polymerase chain reaction–next generation sequencing ctDNA assay (Signatera, Natera, Inc) to evaluate MRD and recurrence. Plasma samples were collected at multiple time points—2 to 12 weeks after surgery and after adjuvant chemotherapy (ACT)—to assess ctDNA positivity, DFS, and patient outcomes.
Key endpoints of the study included the impact of ctDNA testing on treatment decisions, rates of asymptomatic recurrence, MRD clearance, survival of patients without MRD, and overall survival.
Results
Among the study cohort, 62.4% of patients received ACT; 25.9% of patients with stage II and 91.3% of patients with stage III CRC opted for this treatment. A significant association between ctDNA positivity and inferior DFS was observed during both the MRD and surveillance windows, providing critical insights into recurrence risk.
During the MRD window, ctDNA positivity was detected in 8.1% of patients with stage II and 24.9% of those with stage III CRC.
Patients who had ctDNA-positive results had significantly worse DFS compared with those who had ctDNA-negative results:
<ul>
<li>Stage II: Hazard ratio (HR) = 10.4; P&lt;.0001</li>
<li>Stage III: HR = 10.1; P&lt;.0001</li>
</ul>
The 18-month DFS estimates for patients with stages II and III CRC combined were significantly different:
<ul>
<li>Patients without MRD: 93%</li>
<li>Patients with MRD: 44.4%</li>
</ul>
Similar trends were observed during the surveillance period. In the observation cohort, 6.8% of patients with stage II and 33.3% of those with stage III CRC had ctDNA-positive results, with significantly worse DFS (stage II: HR, 34.9; P&lt;.0001; stage III: HR, 34.1; P=.0008).
In the ACT-treated cohort, 10.9% of patients with stage II and 21.1% of those with stage III CRC became ctDNA positive, correlating with significantly reduced DFS (stage II: HR,  131.4; P&lt;.0001; stage III: HR, 54.6; P&lt;.0001).
Implications for Practice
The study highlights ctDNA’s prognostic power in detecting MRD and predicting recurrence risk for patients with CRC. Circulating tumor DNA positivity strongly correlated with inferior DFS, offering a valuable tool for risk stratification and treatment optimization. For patients with ctDNA-positive results after surgery or ACT, enhanced surveillance or more aggressive therapeutic strategies may be warranted. The BESPOKE CRC findings underscore the need for further research into ctDNA-guided treatment strategies.

Emily Menendez

ASPEN-06 Phase 2 Final Analysis Demonstrates Benefit of ALX148 Combination for Gastric Cancer

Gastric Cancer

Stephen V. Liu, MD

Cecilia Brown

Changing Paradigms: Dr. Liu Discusses Implications of MARIPOSA OS Data

EGFR+ NSCLC

Rob Dillard

FDA Approves the First and Only Monotherapy for Treatment-Resistant Depression

Depression

Latest News

CtDNA Shows Promise for Detecting Molecular Residual Disease in Stage II/III Colorectal Cancer: BESPOKE CRC Final Analysis

Colorectal Cancer

The study shows the prognostic value of ctDNA in detecting MRD in patients with stage II/III CRC. 

CtDNA Shows Promise for Detecting Molecular Residual Disease in Stage II/III Colorectal Cancer: BESP

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe